Geron Corporation GERN
At closeNov 4, 2026, 7:20 AM EST
Pre-market · Nov 4, 7:20 AM ET
- YTD
- -29.55%
- 1 year
- -19.13%
- Market cap
- 597.50M
- Revenue (ttm)
- 204.56M
- Profit margin
- -33.05%
- EPS (ttm)
- -0.11
- Shares out
- 642.47M
- Forward P/E
- 39.25
- YTD return
- -29.55%
- 1-year return
- -19.13%
- Volume
- 58.83M
- Avg volume
- 12.08M
- Open
- 0.9411
- Previous close
- 0.9291
- Day's range
- 0.9251 – 0.972
- 52-week range
- 0.84 – 2.01
- Beta
- 0.60
- Price target
- 4.25 (+357.0%)
- Earnings date
- Nov 4, 2026
1m -0.0125 (-1.33%)
Key statistics
- Enterprise value
- 829.98M
- PEG ratio
- 0.00
- Price / sales
- 4.93
- Price / book
- 4.62
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 17.20%
- Free cash flow
- -78.37M
- Total cash
- 300.85M
- Total debt
- 122.14M
- Return on equity
- -28.28%
- Short % of float
- 12.56%
- 50-day average
- 1.47
- 200-day average
- 1.44
Analyst view
- Target (low)
- 3.00
- Target (mean)
- 4.25
- Target (high)
- 6.00
- Strong buy1
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.01.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.01 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -0.00888 | -0.02 | -0.01 | -125.23% |
| May 6, 2026 | Mar 31, 2026 | -0.03 | -0.01 | +0.02 | +66.67% |
| Feb 25, 2026 | Dec 31, 2025 | -0.03 | -0.03 | 0.00 | 0.00% |
| Nov 5, 2025 | Sep 30, 2025 | -0.03667 | -0.03 | +0.01 | +18.19% |
| Aug 6, 2025 | Jun 30, 2025 | -0.03 | -0.02 | +0.01 | +33.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2025 | Needham | main | Buy | Buy |
| May 8, 2025 | Scotiabank | down | Sector Outperform | Sector Perform |
| Mar 12, 2025 | Needham | reit | Buy | Buy |
| Mar 12, 2025 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Feb 27, 2025 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Feb 27, 2025 | Stifel | main | Buy | Buy |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- geron.com
News
Geron Corporation to Participate in the Stifel 2026 Healthcare Conference 
Geron: Opportunity Builds Even As Struggles Continue 
Geron (GERN) Expected to Announce Earnings on Wednesday 
Wedbush Maintains Outperform on Geron, Lowers Price Target to $5 
Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth 
Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth 
Crude Oil Surges Over 3%; Brinker Posts Upbeat Earnings 
Geron discontinues late-stage trial of blood cancer drug 
Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis 
Geron Q2 2026 Earnings Call: Complete Transcript
Your note
Sign in to keep a note on GERN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LAWLIS VIRGIL BRYAN JR. | Director | Purchase | May 8, 2025 | 13,300 |
| ROBERTSON MICHELLE | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 17, 2026 | 17,645 |
| SAMUELS SCOTT ALAN | Officer | Purchase | Feb 26, 2025 | 26,682 |
| SCARLETT JOHN A | Chief Executive Officer | Purchase | Feb 26, 2025 | 137,500 |
| SPIEGEL ROBERT J | Director | Stock Award(Grant) | Jun 29, 2026 | 205,810 |
| ZIEGLER JAMES | Officer | Purchase | Feb 26, 2025 | 100,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.64% | 49,115,571 | 77.11M | Jun 29, 2026 |
| Soleus Capital Management, L.P. | 6.66% | 42,808,659 | 67.21M | Jun 29, 2026 |
| RA Capital Management, L.P. | 6.66% | 42,809,751 | 67.21M | Jun 29, 2026 |
| State Street Corporation | 5.58% | 35,856,671 | 56.29M | Jun 29, 2026 |
| Citadel Advisors Llc | 4.52% | 29,038,928 | 45.59M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.24% | 27,250,215 | 42.78M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.40% | 21,816,987 | 34.25M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 20,449,234 | 32.11M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.25% | 14,478,730 | 22.73M | Jun 29, 2026 |
| Vanguard Explorer Fund | 1.58% | 10,174,592 | 15.97M | Apr 29, 2026 |
| Legg Mason Partners Investment Trust-ClearBridge Small Cap Growth Fund | 0.98% | 6,316,110 | 9.92M | Apr 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.95% | 6,108,370 | 9.59M | Jun 29, 2026 |